Our data identify ferroptosis as a non-NE subtype-specific vulnerability in SCLC and suggest repurposing of combined induction of ferroptosis and TRX pathway inhibition as a strategy to address non-NE/NE SCLC intratumoral heterogeneity and prevent non-NE/NE subtype plasticity under treatment. The gene discussed is TXN; the disease is small cell lung carcinoma.